Combivir - Lamivudine and Zidovudine
Navigation: NDC > Supplier starting with: H > HHS_PROGRAM SUPPORT CENTER_SUPPLY SERVICE CENTER| Field | Value |
|---|---|
| NDC Code: | 11819-359 |
| Proprietary Name: | Combivir |
| Suffix: | |
| Non-Proprietary Name: | Lamivudine and Zidovudine |
| Dosage Form: | TABLET, COATED |
| Method: | ORAL |
| Original Marketing Date: | 30-09-1997 |
| End of Marketing: | 31-07-2014 |
| Category Name: | NDA |
| Application Number: | NDA020857 |
| Labeler: | HHS_PROGRAM SUPPORT CENTER_SUPPLY SERVICE CENTER |
| Substance Name: | LAMIVUDINE; ZIDOVUDINE |
| Active Numerator Strength: | 150; 300 |
| Active Ingredient Unit: | mg/1; mg/1 |
| Pharm Classes: | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| DEA Schedule: |